Background: Leukocyte immunoglobulin-like receptors (LIRs) are members of the immunoglobulin superfamily of glycoproteins and are predominantly expressed by monocytes, B cells, dendritic cells, natural killer (NK) cells, peripheral blood leukocytes and tissues such as placenta, lung and liver. These receptors all contain a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM), have an inhibitory function and are type I membrane proteins. When they bind to MHC (or other ligands) and ITIM is tyrosine phosphorylated, protein-tyrosine phosphatases are recruited and an inhibitory signal cascade triggered. ILT-4, also designated LIR-2, MIR-10 or CD85D antigen, competes with CD8A for binding to class I MHC antigens.
Description: Rabbit polyclonal to LILRB2
Immunogen: KLH conjugated synthetic peptide derived from LILRB2
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 65 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
